[HTML][HTML] Inflammation and cardiovascular disease: From mechanisms to therapeutics

A Alfaddagh, SS Martin, TM Leucker, ED Michos… - American journal of …, 2020 - Elsevier
Inflammation constitutes a complex, highly conserved cascade of molecular and cellular
events. Inflammation has been labeled as “the fire within,” is highly regulated, and is critical …

Cardiovascular disease in diabetes, beyond glucose

RH Eckel, KE Bornfeldt, IJ Goldberg - Cell metabolism, 2021 - cell.com
Despite the decades-old knowledge that diabetes mellitus is a major risk factor for
cardiovascular disease, the reasons for this association are only partially understood. While …

[HTML][HTML] Proprotein convertase subtilisin/kexin type 9: a view beyond the canonical cholesterol-lowering impact

C Macchi, N Ferri, CR Sirtori, A Corsini… - The American journal of …, 2021 - Elsevier
Proprotein convertase subtilisin/kexin type 9 (PCSK9), mainly synthetized and released by
the liver, represents one of the key regulators of low-density lipoprotein cholesterol …

Lipoprotein (a): Knowns, unknowns and uncertainties

M Ruscica, CR Sirtori, A Corsini, GF Watts… - Pharmacological …, 2021 - Elsevier
Over the last 10 years, there have been advances on several aspects of lipoprotein (a)
which are reviewed in the present article. Since the standard immunoassays for measuring …

Lipid lowering drugs: present status and future developments

M Ruscica, N Ferri, RD Santos, CR Sirtori… - Current Atherosclerosis …, 2021 - Springer
Purpose of review Based on the recent data of the DA VINCI study, it is clear that, besides
utilization of statins, there is a need to increase non-statin lipid lowering approaches to …

Effects of PCSK9 targeting: alleviating oxidation, inflammation, and atherosclerosis

E Punch, J Klein, P Diaba‐Nuhoho… - Journal of the …, 2022 - Am Heart Assoc
Characterized as a chronic inflammatory disease of the large arteries, atherosclerosis is the
primary cause of cardiovascular disease, the leading contributor of morbidity and mortality …

PCSK9 and atherosclerosis: Looking beyond LDL regulation

R Ragusa, G Basta, D Neglia… - European journal of …, 2021 - Wiley Online Library
Abstract Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) is involved in cholesterol
homeostasis. After binding to the complex low‐density lipoprotein (LDL)‐receptor, PCSK9 …

Monomeric C-reactive protein in atherosclerotic cardiovascular disease: advances and perspectives

I Melnikov, S Kozlov, O Saburova, Y Avtaeva… - International journal of …, 2023 - mdpi.com
This review aimed to trace the inflammatory pathway from the NLRP3 inflammasome to
monomeric C-reactive protein (mCRP) in atherosclerotic cardiovascular disease. CRP is the …

[HTML][HTML] Safety of PCSK9 inhibitors

G Grześk, B Dorota, Ł Wołowiec, A Wołowiec… - Biomedicine & …, 2022 - Elsevier
Abstract annually in Europe, 4 million people die from cardiovascular diseases, the main
cause of which is atherosclerosis. In order to slow down the development of atherosclerotic …

An update on the role of PCSK9 in atherosclerosis

E Yurtseven, D Ural, K Baysal… - Journal of atherosclerosis …, 2020 - jstage.jst.go.jp
910 levels, whereas PCSK9 overexpression did not cause an increase in plasma lipids but
in atherosclerotic lesion size18, 19). The Atheroma IVUS study revealed that the necrotic …